Table VI.
Frequency (%) of tetramer+ CD4+ cells from the following groupa | ||||||
---|---|---|---|---|---|---|
Immunized |
Control |
|||||
Cell sourceb | 3892 | 3937 | 3943 | 3959 | 3962 | 3989 |
PBMC (pre-immunization) | 0.0009 | 0.0003 | 0.0020 | 0.0005 | ||
PBMC (challenge) | 0.0361 | 0.0090 | 0.0324 | 0.0206 | 0.0015 | 0.0001 |
PBMC (death) | 0.0003 | 0.0002 | 0.0003 | 0.0003 | 0.0006 | 0.0002 |
Spleen (death) | 0.0004 | 0.0018 | 0.0048 | 0.0003 | 0.0006 | NDc |
LN (death) | 0.0013 | 0.0001 | 0.0026 | 0.0003 | 0.0018 | 0.0007 |
Liver (death) | 0.0019 | 0.0027 | 0.0032 | 0.0021 | NDc | 0.0009 |
Cryopreserved lymphocytes were thawed, and viable cells stained with the *1101-F2-5B tetramer. The percentage of tetramer+ CD4+ cells of total CD4+ T cells was calculated. Numbers in bold represent significantly higher mean frequencies of tetramer+ CD4+ T cells in compared with those in PBMC pre-immunization using a one-tailed paired t-test (P= 0.008 for liver and P= 0.014 for PBMC at the time of challenge).
Cryopreserved PBMC were obtained before immunization, on the day of challenge (day 321 post immunization; animals 3892, 3937, 3989, 3962), 5 days post-challenge (animal 3943), 12 days post-challenge (animal 3959), and at the time of death (day 63, animals 3892 and 3962; day 69, animal 3937; day 75, animal 3943; day 84, animal 3959, and day 89 post-challenge, animal 3989).
Not determined because of insufficient cell numbers.